Study Design: Pharmacy claims were compared over one year between a cohort of GeneSight tested subjects (n = 2,168 enrolled) and a control group (n = 10,880). Both groups were followed for 365 days after the date of project enrollment. Prescription medication claims data was analyzed for differences between the two groups and within the GeneSight group based on medication changes that were congruent or non-congruent with each individual’s GeneSight results.
Significant annual savings are realized when healthcare providers use GeneSight test results to guide treatment decisions: Patients who received GeneSight testing saved $1,035.60 in total annual medication costs compared to TAU patients. Total annual medication savings were $714.24 (69%) for non-CNS medications and $321.36 (31%) for CNS medications.
Improvement in Adherence: An increase in medication adherence of 17% was observed in the GeneSight group (p < 0.0001) for the medication prescribed after enrollment compared to the medication prescribed prior to enrollment.
Reduced Polypharmacy: One in five patients in the GeneSight group were on less medications by the end of the study (significantly greater than the empiric prescribing cohort, p < 0.0001).
Provider congruence with GeneSight report recommendations results in lower medication costs: GeneSight guided patients with congruent medication regimens saw an average of $2,774.53 in net annual cost savings compared to patients with incongruent medication regimens.
Works across Practice Settings and Conditions: Both psychiatrists and non-psychiatrists who had access to GeneSight information saw average savings of over $1,000 per patient. Savings for major depressive disorder, anxiety, and bipolar disorder conditions averaged over $1,000. GeneSight cost savings effect increases as a function of congruence with the report.